Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 1Hypotension 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 58Nivolumab 37aldesleukin 16Cyclophosphamide 15atezolizumab 12Specimen Handling 11Radiosurgery 10Paclitaxel 10Magnetic Resonance Spectroscopy 10Ipilimumab 9Interleukin-2 9fludarabine 8fludarabine phosphate 7Docetaxel 7Carboplatin 7avelumab 6Radiotherapy 6durvalumab 5Peripheral Blood Stem Cell Transplantation 5Immune Checkpoint Inhibitors 5Cisplatin 5Bevacizumab 5tislelizumab 4temsirolimus 4spartalizumab 4Sirolimus 4Pemetrexed 4Oxaliplatin 4Leucovorin 4Cryosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × imisopasem manganese × Dermatologic × Clear all
NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡